CSV May 5, 2023 through May 5, 2025 See all Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CEFDINIR FOR	ADDITIONAL R	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORAL SUSPENSION	EQUIREMENTS							*Reference Standards* ?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42 AND In *USP Reference Standards* ?11?/USP Cefdinir Related Compound B RS: Change $C_{14}H_{13}N_4O_4S_2$ 365.41 to: $C_{14}H_{14}N_4O_4S_2$ 366.41
CEFUROXIME AXETIL FOR ORAL SUSPENSION	ASSAY	*USPNF Online*	Online	31-May-2024	1-Jun-2024	*NA*	*NA*	In *Procedure*/*System suitability*: Change [Note—The relative retention times for acetanilide,

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								cefuroxime axetil diastereoisomer B, cefuroxime axetil diastereoisomer A, and cefuroxime axetil delta-3 isomers are 0.4, 0.8, 0.9, and 1.0, respectively.] to: [Note—The relative retention times for cefuroxime axetil diastereoisomer B, cefuroxime axetil diastereoisomer A, and cefuroxime axetil delta-3 isomers are 0.8, 0.9, and 1.0, respectively.]
CETIRIZINE HYDROCHLORID	IMPURITIES	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Organic Impurities,*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E								*Procedure 2*/*Solution A*: Change tetrabutyl ammonium to: tetrabutylammonium
CETIRIZINE HYDROCHLORIDE TABLETS	IMPURITIES	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Organic Impurities*/*Buffer*: Change tetrabutyl ammonium to: tetrabutylammonium
CHLORTETRACYCLINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	Change 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride to: (4*S*,4a*S*,5a*S*,6*S*,12a*S*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-7-Chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide monohydrochloride
CLOMIPHENE CITRATE TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	In *Table 2*: Change Clomiphene related compound A 0.87 – 2.0 to: Clomiphene related compound A 0.87 1.0 2.0
COCOYL CAPRYLOCAPRATE	SPECIFIC TESTS	*USPNF Online*	Online	23-Feb-2024	1-May-2024	*NA*	*NA*	In *Fats and Fixed Oils* ?401?, *Procedures*, *Hydroxyl Value*/*Analysis*: Change Calculate the acid value as directed in the

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chapter. to: Calculate the hydroxyl value as directed in the chapter.
COSYNTROPIN	IDENTIFICATION	*USPNF Online*	Online	28-Mar-2025	1-Apr-2025	*NA*	*NA*	In *B. Amino Acid Analysis*/*System suitability*/*Resolution*: Change (*hp* ? *hv*)/*hp* × 100 ± 90%, to: (*hp* ? *hv*)/*hp* × 100 ? 90%,
CRANBERRY FRUIT DRY JUICE	COMPOSITION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Content of Pr* /*Standard stock solution*: Change USP Procyanidin A_2 RS to: USP Procyanidin A2

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS AND In *Content of Pr*
								/*Analysis*: Change Use the absorbance recorded for *Standard solutions 1–5* to obtain a calibration curve (absorbance vs. concentration, in µg/mL, of procyanidin A_2) and perform a linear regression analysis. Determine the concentration (*C*), in µg/mL, of total proanthocyanidins as procyanidin A_2 in the *Sample*

Monograph Title	Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution. to: Use the absorbance recorded for *Standard solutions 1–5* to obtain a calibration curve (absorbance vs. concentration, in µg/mL, of procyanidin A2) and perform a linear regression analysis. Determine the concentration (*C*), in µg/mL, of total proanthocyanidins as procyanidin A2 in the *Sample solution*. AND In *Content of Pr*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								/Analysis: Change *C* = concentration of the *Sample solution* as procyanidin A_2 from the regression line (µg/mL) to: *C* = concentration of the *Sample solution* as procyanidin A2 from the regression line (µg/mL) AND In *Content of Pr*
CRANBERRY FRUIT DRY	ADDITIONAL REQUIREMENT	*USPNF Online* Online		25-Aug-2023	1-Sep-2023	*NA*	*NA*	*/Acceptance criteria*: Change procyanidin A_2 to: procyanidin A2 In *USP Reference*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
JUICE	S							*Standards* ?11?: Change USP Procyanidin A_2 RS to: USP Procyanidin A2 RS
CRANBERRY FRUIT DRY JUICE	DEFINITION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	Change procyanidin A_2 to: procyanidin A2
CRANBERRY FRUIT DRY JUICE	IDENTIFICATION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *A./Standard solution B*: Change USP Procyanidin A_2 RS to: USP Procyanidin A2 RS AND In *A./System suitability/Suitability requirements/Derivatization*

Monograph Title	Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								reagent B/*White light*: Change *Standard solution B* exhibits two brown bands in the upper-half section corresponding to procyanidin A_2 and epicatechin. *Standard solution C* exhibits two brown bands in the upper-half section corresponding in R_F and color to procyanidin A_2 and epicatechin in *Standard solution B*. *Standard solution C* also exhibits a series of faint or indistinct brown bands of

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								differing intensities below procyanidin A_2 in the lower-half section. to: *Standard solution B* exhibits two brown bands in the upper-half section corresponding to procyanidin A2 and epicatechin. *Standard solution C* exhibits two brown bands in the upper-half section corresponding in R_F and color to procyanidin A2 and epicatechin in *Standard solution B*. *Standard*

Monograph Title	Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution C also exhibits a series of faint or indistinct brown bands of differing intensities below procyanidin A2 in the lower-half section. AND In *A./ Acceptance criteria/ Derivatization reagent B*/*White light*: Change The *Sample solution* exhibits two faint brown bands corresponding in R_F to procyanidin A_2 and epicatechin in *Standard solution B*. The *Sample solution* also exhibits a series of faint or

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								indistinct brown bands of differing intensities in the lower-half section, corresponding to the same bands in *Standard solution C*. No bands corresponding in R_F to epigallocatechin-3-*O*-gallate, procyanidin B_2, or procyanidin B_1 appear below procyanidin A_2. to: The *Sample solution* exhibits two faint brown bands corresponding in R_F to procyanidin A2 and epicatechin

Monograph Title	Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in *Standard solution B*. The *Sample solution* also exhibits a series of faint or indistinct brown bands of differing intensities in the lower-half section, corresponding to the same bands in *Standard solution C*. No bands corresponding in R_F to epigallocatechin-3-*O*-gallate, procyanidin B2, or procyanidin B1 appear below procyanidin A2. AND In *C./ Acceptance criteria/Profile at*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								520 nm: Change cyani din-3-*O* -arabinose, to: cyani din-3-*O* -arabinoside, AND In *C./ Acceptance criteria/Profile at 520 nm*: Change peon idin-3-*O* -arabinose to: peon idin-3-*O* -arabinoside
CRANBERRY FRUIT JUICE DRY EXTRACT	IDENTIFICATION	*USPNF Online*	Online	26-Jul-2024	1-Aug-2024	*NA*	*NA*	In *A. HPTLC for Articles of Botanical Origin <203>/Sample solution*: Change Mix 50 mg of Cranberry Fruit Juice Dry

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Extract with 7 mL of water. Sonicate for 10 min at room temperature, centrifuge, and save the supernatant. Precondition an SPE cartridge (L2; 500 mg/6 mL) with 3 mL of methanol, and drain it with suction. Load 3 mL of water onto the cartridge and apply suction until the solvent reaches 1–2 mm above the top of the cartridge's stationary phase. Then load the cartridge with 1.5 mL of the supernatant, apply suction,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and discard the eluate. Add 1 mL of a mixture of water and methanol (80:20). Load 1 mL of methanol and collect the eluate as the *Sample solution*. to: Mix 50 mg of Cranberry Fruit Juice Dry Extract with 7 mL of water. Sonicate for 10 min at room temperature, centrifuge, and save the supernatant. Precondition an SPE cartridge (L2; 500 mg/6 mL) with 3 mL of methanol, and drain it with suction. Load 3 mL of water

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								onto the cartridge and apply suction until the solvent reaches 1–2 mm above the top of the cartridge's stationary phase. Then load the cartridge with 1.5 mL of the supernatant, apply suction, and discard the eluate. Add 1 mL of a mixture of water and methanol (80:20), apply suction, and discard the eluate. Load 1 mL of methanol and collect the eluate as the *Sample solution*.
DAPSONE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Dissolution* ?711?/*Standard*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Change USP Dapsone RS of a known concentration in *Medium* to: (*L*/1000) mg/mL of USP Dapsone RS in *Medium*, where *L* is the label claim in mg/Tablet. Transfer a portion of this solution containing 0.2 mg of dapsone to a 25-mL volumetric flask, add 5 mL of 1 N sodium hydroxide, and dilute with water to volume.
DESCRIPTION AND SOLUBILITY	Hydrogenated Castor Oil	*USPNF Online*	Online	28-Jun-2024	1-Aug-2026	*NA*	*NA*	Change White, crystalline wax. Freely soluble in water, in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								saline TS, and in dextrose solutions; very slightly soluble in alcohol; practically insoluble in chloroform and in ether. Insoluble in water and in most common organic solvents. *NF category*: Stiffening agent; lubricant; film-forming agent; r elease-modifying agent.
								to: White, crystalline wax. Insoluble in water and in most common organic solvents. *NF category*: Stiffening agent;

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lubricant; film-forming agent; release-modifying agent.
DEXTROMETHORPHAN HYDROBROMIDE ORAL SOLUTION	*Assay*	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Chromatographic system* and *Procedure*: Change *C* is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS, on the anhydrous basis, in the *Standard preparation*; to: *C* is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS in the *Standard preparation*;

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIBUCAINE	CHROMATOGRAPHIC PURITY	*USPNF Online*	Online	27-Dec-2024	1-Jan-2025	*NA*	*NA*	Change Proceed as directed for *Chromatographic purity* under *Dibucaine Hydrochloride*, to: Proceed as directed for *Organic Impurities* under *Dibucaine Hydrochloride*,
DICLOFENAC SODIUM AND MISOPROSTOL DELAYED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?: Move *Test 2* after *Test 1*
DICYCLOMINE HYDROCHLORIDE	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *B. Identification Tests—General* ?191?, *Chemical Identification Tests*, *Chloride*: Change Meets the requirements when tested as

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								specified in test *B*. to: Meets the requirements of the test for amine hydrochlorides
DIGOXIN TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In *Chromatographic system*: Change **Column:** 4.2-mm × 25-cm; 5-?m packing L1 to: **Column:** 4.6-mm × 25-cm; 5-µm packing L1
DIGOXIN TABLETS	ASSAY	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Procedure/Analysis*: Change C_U = nominal concentration of in the *Sample solution* (µg/mL) to:

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = nominal concentration of digoxin in the *Sample solution* (µg/mL)
DILUTED ISOSORBIDE MONONITRATE	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impurities/Standard solution*: Change isosorbide related compound A to: isosorbide mononitrate related compound A AND In *System suitability/Suitability requirements/Relative standard deviation*: Change isosorbide related compound A, to:

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								isosorbide mononitrate related compound A, AND In four instances in *Analysis*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In *Table 1*: Change Isosorbide related compound A to: Isosorbide mononitrate related compound A
DIMETHYL SULFOXIDE	SPECIFIC TESTS	*USPNF Online*	Online	28-Mar-2025	1-Apr-2025	*NA*	*NA*	In *Acidity/ Sample solution*: Change 500 mg/mL of Dimethyl

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	Sulfoxide in water to: 50.0 g of Dimethyl Sulfoxide in 100 mL of water In *Dissolution* ?711?/*Test 8*/*Tolerances*: Change The percentage of the labeled amount of valproic acid ($C_8H_{16}O_2$) dissolved at the times specified conform to *Dissolution* <711>, *Acceptance Table 1*. to: The percentage of the labeled amount of valproic acid ($C_8H_{16}O_2$) dissolved at the times specified

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								conform to *Dissolution* <711>, *Acceptance Table 2*.
DOCETAXEL	IMPURITIES	*USPNF Online*	Online	31-May-2024	1-Jun-2024	*NA*	*NA*	In *Organic Impurities*, *Procedure 1*: Change **System suitability solution, Standard solution, Sample solution,** and **Chromatographic system:** Proceed as directed in the *Assay*. to: **Mobile phase, Diluent, System suitability solution, Standard solution, Sample solution,**

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and **Chromatographic system:** Proceed as directed in the *Assay*.
DOXORUBICIN HYDROCHLORIDE	ASSAY	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Procedure*/*System suitability solution*: Add link to USP Store for USP Epirubicin Hydrochloride RS
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Dihydrodutasteride RS: Change *N* -[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androst-1-ene-17?-carboxamide. to: *N*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androstane-17?-carboxamide. In *Dissolution* ?711?/*Test for dutasteride*/*Tier 2*/*Medium*: Change 10 g/L of cetyltrimethylammonium bromide and 750,000 USP units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of cetyltrimethylammonium bromide and 1.6 g of pepsin, purified in 1000 mL of 0.1 N hydrochloric acid; 900 mL
EDETATE	DEFINITION	*USPNF Online*	Online	28-Jun-2024	1-Jul-2024	*NA*	*NA*	In two

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DISODIUM COMPOUNDED OPHTHALMIC SOLUTION								instances: Change to a pH between 6.5 and 7.5. to: to a pH between 6.1 and 7.1.
ENSULIZOLE	IDENTIFICATION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *B*.: Change The retention time of the major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution*, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								that of the *Standard solution*, as obtained in the *Assay*.
EXENATIDE INJECTION	PRODUCT-RELATED SUBSTANCES AND IMPURITIES	*USPNF Online*	Online	26-Jul-2024	1-Aug-2024	*NA*	*NA*	In *Procedure*/*Chromatographic system*/*Column*: Change 4.6-mm × 10-cm; 3-µm packing L52 to: 4.6-mm × 10-cm; 3-µm packing L52; two columns in series
FLUCONAZOLE	IMPURITIES	*USPNF Online*	Online	25-Oct-2024	1-Nov-2024	*NA*	*NA*	In *Organic Impurities*/*Analysis*: Change Calculate the percentage of any individual unspecified impurity in the portion of

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Fluconazole taken: to: Calculate the percentage of any other specified and unspecified impurity in the portion of Fluconazole taken: AND Change r_U = peak response of any individual impurity from the *Sample solution* to: r_U = peak response of any other specified and unspecified impurity from the *Sample solution*
FLUCONAZOLE TABLETS	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *USP Reference Standards*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<*11*>/USP Fluconazole Related Compound B RS: Change $C_{13}H_{13}FN_9O$ to: $C_{13}H_{13}FN_6O$
FLURAZEPAM HYDROCHLORIDE	USP REFERENCE STANDARDS ?11?	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In USP Flurazepam Related Compound C RS: Change 5-Chloro-2-(2-diethylaminoethyl(amino)-2?-fluorobenzophenone hydrochloride. to: 5-Chloro-2-(2-diethylaminoethylamino)-2?-fluorobenzophenone hydrochloride.
FOSAMPRENAVIR CALCIUM TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Dissolution* ?711?/*Medium*: Change 26.7 g/L of sodium acetate trihydrate in water. Add 133

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL. to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows. Dissolve 2.67 g of sodium acetate in 100 mL of water. Add 13.3 mL of glacial acetic acid and then dilute with water to 1000 mL; 900 mL.
GLUCAGON	PROCESS-RELATED IMPURITIES AND OTHER COMPONENTS	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Acetic Acid in Peptides/Analysis*: Change C_{SPA} = concentration of potassium acetate in each of the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solutions (mg/mL) to: C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (µg/mL) AND In *Ammonium/ Analysis*: Change C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (mg/mL) to: C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (µg/mL)

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLYCYL-L-TYROSINE	IMPURITIES/*Related Compounds*	*USPNF Online*	Online	24-Feb-2023	1-Jun-2023	*NA*	*NA*	In *Buffer solution*: Change Dissolve 6.84 g of potassium phosphate in 1000 mL of water. to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of water.
HYDROXYPROPYL BETADEX	IMPURITIES	*USPNF Online*	Online	31-Jan-2025	1-Feb-2025	*NA*	*NA*	In *Limit of Betadex, Propylene Glycol, and Other Related Substances/ Chromatographic system*: Change **Column temperature:** 40° to: **Temperatures**

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INDOMETHACIN SODIUM	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	22-Nov-2024	1-Dec-2024	*NA*	*NA*	**Detector:** 40° **Columns:** 40° In *USP Reference Standards ?11?*/USP Indomethacin Related Compound A RS: Change ($C_{12}H_{13}NO_3$) to: $C_{12}H_{13}NO_3$ AND In *USP Reference Standards ?11?*/USP Indomethacin Related Compound B RS: Change ($C_7H_5ClO_2$) to: $C_7H_5ClO_2$
IODIXANOL INJECTION	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Iodixanol

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IODIXANOL	IMPURITIES	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	Related Compound E RS: Change 5-[[3-[[3-[[(2,3-Dihydroxypropyl)amino]carbonyl]-5- [[amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl]-(acetylimino)]-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide. to: 5-{*N*-[3-(*N*-{3-Carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-N^1,N^3-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide. In *Organic*

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION								*Impurities, Procedure 2*/footnote 4: Change 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl](acetylimino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hy droxypropyl]oxy]-2-hydroxypropyl](acetylimino)]-*N*,*N*'-bis(2,3-dihy dr oxypropyl)-2,4,6-triiodo-1,3-benzendicarboxamide. to: 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]-2,4,6-triiodophenyl](acetylamino)]-2-hydroxypropyl](acetylamino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hydroxypropyl]oxy]-2-hydroxypropyl](acetylamino)]-*N*,*N*'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide.
IOPAMIDOL INJECTION	USP REFERENCE STANDARDS <11>	*USPNF Online*	Online	28-Mar-2025	1-Apr-2025	*NA*	*NA*	In USP Iopamidol Related Compound B RS: Change *N*,*N*?-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodoisophthala

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mide. $C_{16}H_{20}I_3N_3O_7$ 747.07 to: N^1,N^3 -Bis(1,3-dihydroxypropan-2-yl)-5-(2-hydroxyacetamido)-2,4,6-triiodoisophthalamide. $C_{16}H_{20}I_3N_3O_8$ 763.06
IPRATROPIUM BROMIDE INHALATION SOLUTION	IMPURITIES	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Organic Impurities*: Change **Column:** 4.6-mm × 25-µm; 5-µm packing L1 to: **Column:** 4.6-mm × 25-cm; 5-µm packing L1
ISOSORBIDE MONONITRATE TABLETS	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impurities*/*Standard solution*: Change

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								isosorbide related compound A to: isosorbide mononitrate related compound A AND In *System suitability/Suitability requirements/Relative standard deviation*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In four instances in *Analysis*: Change isosorbide related

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound A, to: isosorbide mononitrate related compound A, AND In *Table 1*: Change Isosorbide related compound A to: Isosorbide mononitrate related compound A
KETOCONAZOLE	ASSAY	*USPNF Online*	Online	27-Sep-2024	1-Oct-2024	*NA*	*NA*	In *Procedure*/*Buffer*: Change tetrabutyl ammonium to: tetrabutylammonium
LEVORPHANOL TARTRATE TABLETS	PERFORMANCE TESTS/ *Uniformity of Dosage Units* ?905?	*USPNF Online*	Online	31-Mar-2023	1-Aug-2023	*NA*	*NA*	In *Sample solution*: Change Nominally about 80 ug/mL of levorphanol tartrate in

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluent prepared as follows. to: Nominally about 80 µg/mL of levorphanol tartrate in *Diluent* prepared as follows.
LIDOCAINE	ASSAY	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Procedure*: Change **Column:** 3.9-mm × 30-cm; 4-µm packing L1 to: **Column:** 3.9-mm × 30-cm; 10-µm packing L1
LIDOCAINE, RACEPINEPHRINE AND TETRACAINE HYDROCHLORIDES COMPOUNDED TOPICAL GEL	DEFINITION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	Change Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel

Monograph Title	Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Sterile Preparations* <797>). to: Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Nonsterile Preparations* <795>).
LINEZOLID TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	In *Sensitivity solution*: Change 0.5 ug/mL of USP Linezolid RS from *Standard solution* in *Diluent* to: 0.5 ?g/mL of USP Linezolid RS from *Standard solution* in *Diluent*
LINEZOLID TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *Dissolution* ?711?/*Test 1*/*Analysis*: Change Result = (*r*

Monograph Title	Section Sort descending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U/r_S$) × C_S × V × (1/L) × 100 r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900 mL L = label claim (mg/Tablet) to: Result = (r_U/r_S) × C_S × V × (1/L) × D × 100 r_U = peak response of

Monograph Title Sort descending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) *V* = volume of *Medium*, 900 mL *L* = label claim (mg/Tablet) *D* = dilution factor of the *Sample solution*, as needed

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1